The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2004-04-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chromaderm, Inc.; Eli Lilly and Company
• Treatments: Ruboxistaurin

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Greater than or equal to 30 years of age

• Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.

Exclusion Criteria:

• Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females

• B/P greater than 150 systolic and greater than 90 diastolic

• Hemoglobin Alc greater than 11%

• Liver Function Tests 2 times upper limit of normal

• Poor medical or psychiatric risk.